Cargando…
Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society for Microbiology
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7269515/ https://www.ncbi.nlm.nih.gov/pubmed/32312781 http://dx.doi.org/10.1128/AAC.00754-20 |
| _version_ | 1783541775014559744 |
|---|---|
| author | Hoffmann, Markus Schroeder, Simon Kleine-Weber, Hannah Müller, Marcel A. Drosten, Christian Pöhlmann, Stefan |
| author_facet | Hoffmann, Markus Schroeder, Simon Kleine-Weber, Hannah Müller, Marcel A. Drosten, Christian Pöhlmann, Stefan |
| author_sort | Hoffmann, Markus |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7269515 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | American Society for Microbiology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-72695152020-06-09 Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19 Hoffmann, Markus Schroeder, Simon Kleine-Weber, Hannah Müller, Marcel A. Drosten, Christian Pöhlmann, Stefan Antimicrob Agents Chemother Letter to the Editor American Society for Microbiology 2020-05-21 /pmc/articles/PMC7269515/ /pubmed/32312781 http://dx.doi.org/10.1128/AAC.00754-20 Text en Copyright © 2020 American Society for Microbiology. All Rights Reserved (https://doi.org/10.1128/ASMCopyrightv2) . https://doi.org/10.1128/ASMCopyrightv2 This article is made available via the PMC Open Access Subset for unrestricted noncommercial re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Letter to the Editor Hoffmann, Markus Schroeder, Simon Kleine-Weber, Hannah Müller, Marcel A. Drosten, Christian Pöhlmann, Stefan Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19 |
| title | Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19 |
| title_full | Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19 |
| title_fullStr | Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19 |
| title_full_unstemmed | Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19 |
| title_short | Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19 |
| title_sort | nafamostat mesylate blocks activation of sars-cov-2: new treatment option for covid-19 |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7269515/ https://www.ncbi.nlm.nih.gov/pubmed/32312781 http://dx.doi.org/10.1128/AAC.00754-20 |
| work_keys_str_mv | AT hoffmannmarkus nafamostatmesylateblocksactivationofsarscov2newtreatmentoptionforcovid19 AT schroedersimon nafamostatmesylateblocksactivationofsarscov2newtreatmentoptionforcovid19 AT kleineweberhannah nafamostatmesylateblocksactivationofsarscov2newtreatmentoptionforcovid19 AT mullermarcela nafamostatmesylateblocksactivationofsarscov2newtreatmentoptionforcovid19 AT drostenchristian nafamostatmesylateblocksactivationofsarscov2newtreatmentoptionforcovid19 AT pohlmannstefan nafamostatmesylateblocksactivationofsarscov2newtreatmentoptionforcovid19 |